Halozyme Reports Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital
August 10, 2021 9:04 AM EDTBMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $66.00 (from $64.00) while maintaining an Outperform rating.
The analyst commented, "HALO reported 2Q21 royalty revenues of $45.8mn, ahead of our $40.9mn estimate and consensus' $45.4mn. 2021 guidance was also revised... More
Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
August 9, 2021 4:05 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41.... More
